SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Adamis Pharmaceuticals to Present at Conferences in June 2019
[May 29, 2019]

Adamis Pharmaceuticals to Present at Conferences in June 2019


SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that management is scheduled to present a company overview at two upcoming conferences in June 2019.  During the conferences, management from Adamis will discuss the company’s business, regulatory and operational developments.

Details of the conference presentations are as follows:

Event:9th Annual LD Micro Invitational Conference 
Date:Tuesday, June 4, 2019
Time:11:00 a.m. Pacific Time (2:00 p.m. Eastern Time)
Location:Luxe Htel in Los Angeles, California
  
Event:Raymond James Life Sciences and MedTech Conference 
Date:Tuesday, June 18, 2019
Time: 10:15 a.m. Pacific Time (1:15 p.m. Eastern Time)
Location:Lotte New York Palace, New York, New York



About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy.  The company’s SYMJEPITM (epinephrine) Injection 0.3mg and SYMJEPITM (epinephrine) Injection 0.15mg products were approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis.  Adamis previously announced a distribution and commercialization agreement with Sandoz, a division of Novartis Group, to market Symjepi in the U.S.  Adamis is developing additional products, including a naloxone injection product candidate for the treatment of opioid overdose, a sublingual tadalafil product candidate for the treatment of erectile dysfunction, and a metered dose inhaler and dry powder inhaler product candidates for the treatment of asthma and COPD.  The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for use by hospitals, clinics and surgery centers throughout most of the United States.


Adamis Contacts

Mark Flather
Senior Director, Investor Relations &
Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
mflather@adamispharma.com

Primary Logo


[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy